69 results about "Tumour volume" patented technology

The invention discloses a tumor radiotherapy effect evaluation method and system based on machine learning. The method comprises the following steps: collecting clinical information of a patient; performing data preprocessing on the clinical information of the patient to obtain standard patient data; according to the standard patient data, a chi-square test model is adopted for screening, and patient data features related to prediction indexes are obtained; inputting the patient data features into a pre-constructed multi-task deep learning model, inputting screened features, and predicting the survival state of the patient after radiotherapy to obtain a tumor volume estimation result; wherein the tumor volume estimation result comprises tumor prediction results of a first period, a second period and a third period after treatment; wherein the multi-task deep learning model is a model obtained by training according to an original sample. According to the method, the labeling quantity of the medical image is increased, and the labeling efficiency is improved.

The invention discloses a hepatobiliary tumor follow-up visit data processing service system, and relates to the technical field of hepatobiliary tumor follow-up visit data processing. A data collection module is used for collecting hepatobiliary tumor growth and change conditions of a current patient in a current follow-up visit period; the tumor volume change rate OBL, the tumor growth speed OTS and the tumor growth predicted value OY are sequentially calculated and output, the change trend of the liver and gall tumors of the current patient is observed, basic data are provided for follow-up visit diagnosis and treatment, and the current patient is in the next follow-up visit period through a data prediction processing module. And taking the tumor growth predicted value OY of the last follow-up period as an input value of the tumor volume Ostart when follow-up of the next follow-up period starts to form continuous calculation of follow-up, so that efficient and accurate processing and analysis of tumor data are realized, the prediction accuracy is improved, and errors generated by prediction are corrected and adjusted in time; and more accurate treatment suggestions are provided for patients.

A computer-implemented method comprising: obtaining a three-dimensional model of a subject, the model comprising voxels; identifying a gross tumor volume for the three-dimensional model, the gross tumor volume representing a current location of a tumor in the subject; identifying a primary clinical target volume for the three-dimensional model, the primary clinical target volume having a larger volume than the gross tumor volume, the primary clinical target volume representing an approximation of the current location of the tumor in the subject; identifying a predictive clinical target volume for the three-dimensional model, the predictive clinical target volume having a larger volume than the primary clinical target volume, the predictive clinical target volume representing a predicted future location of the tumor in the subject; and selecting at least one transducer layout for delivering tumor treating fields to the subject based on the primary clinical target volume and the predictive clinical target volume.

A similarity-based deformable registration of a medical image containing a tumor region typically undesirably results in an unproportionate volume change in the tumor region. An image registration framework for preserving tumor volume while facilitating similarity in non-tumor portions is provided. The framework involves a two-stage process. In a first stage, similarity-based registration is used to identify potential tumor regions by their volume changes, thereby generating a soft tumor mask accordingly. In a second stage, a volume-preserving registration network is used. The network uses a novel adaptive volume retention loss that adaptively treats a change in size based on the mask calculated in the previous stage. The framework balances image similarity and volume retention in different regions, i.e., non-tumor regions and tumor regions, by using a soft tumor mask to adjust the volume retention loss applied to each region. It ensures that the tumor volume is retained during the registration process.

The present invention relates to a method to improve the anti-tumour effects of immune checkpoint therapy by combining the use of a checkpoint inhibitor with ultralow dose whole body irradiation. The present invention enhances the anti-tumour effects of immune checkpoint therapy by reducing tumour volume as well as shortening the response time of the immune checkpoint therapy, as compared to immune checkpoint therapy on its own.

The invention relates to a composition and related methods for enhancing the immune response and / or decreasing the size or growth rate of a tumor volume in a subject. The composition comprises a recombinant MVA encoding IL-12 and, optionally, a Tumor Associated Antigen (“TAA”). In some embodiments, the MVA also encodes 4-1BBL and / or a second MVA encoding 4-1BBL is coadministered to the subject. In some embodiments of the invention, methods comprise injecting these MVAs intratumorally. In some embodiments, the recombinant MVAs are injected intraperitoneally to stimulate an immune response to peritoneal tumors.

The application relates to the technical field of biological medicine, and discloses a micropeptide miPEP060 coded by a LINC00060 gene and application thereof; the application provides the following application of LINC00060 and the micropeptide miPEP060 coded thereby: preparing a product for predicting tumor chemotherapy efficacy, preparing a product for predicting tumor prognosis; preparing a tumor treatment product, preparing a product for enhancing tumor chemotherapy efficacy, preparing a product for overcoming tumor chemotherapy drug resistance, preparing a product for inhibiting PARP1 enzyme activity or PARylation modification, and preparing a product for inhibiting replication stress response and replication fork stability; the LINC00060 and the micropeptide miPEP060 coded thereby provided by the application can significantly enhance the chemotherapy killing effect of tumor cells or tumor tissues and reduce tumor volume.

Compositions, kits, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating electric field in combination with administration of at least one composition comprising interferon gamma.

A computer-implemented method comprising: obtaining a three-dimensional model of a subject, the model comprising voxels; identifying a gross tumor volume for the three- dimensional model, the gross tumor volume representing a current location of a tumor in the subject; identifying a primary clinical target volume for the three-dimensional model, the primary clinical target volume having a larger volume than the gross tumor volume, the primary clinical target volume representing an approximation of the current location of the tumor in the subject; identifying a predictive clinical target volume for the three-dimensional model, the predictive clinical target volume having a larger volume than the primary clinical target volume, the predictive clinical target volume representing a predicted future location of the tumor in the subject; and selecting at least one transducer layout for delivering tumor treating fields to the subject based on the primary clinical target volume and the predictive clinical target volume.

The name of the invention is compositions and methods for enhancing cancer radiotherapy. A nutritional supplement comprising fish oil and selenium has been determined to enhance radiotherapy of tumors in a synergistic manner. The co-therapy of such supplements and radiotherapy results in a significantly improved reduction in tumor volume in animal models and reduces the common side effects, such as weight loss, inflammation and gastrointestinal tract damage, relative to radiotherapy alone. It has also been found that this co-therapy can reduce the incidence of metastasis from a primary implant site and modulate the expression of genes associated with apoptosis in tumor cells. Formulations of such supplements with good tolerance and palatability are also provided.

The present disclosure relates to representation learning for treatment response prediction of risk organs and total tumor volume. For predicting the response of radiation therapy, radiomics is used for unsupervised machine training of an encoder-decoder network to predict based on input of image data, such as computed tomography image data, and from segmentation. Then, the trained encoder is used to generate latent representations to be used as input to different classifiers or regressors for predicting the treatment response, such as one classifier for predicting the response for a risk organ and another classifier for predicting another type of response for a risk organ or predicting the response for a tumor.

The invention relates to a predictive gene expression signature of response to antiangiogenic drugs, such as axitinib, in gastro-enteric-pancreatic and pulmonary neuroendocrine tumours. The signature is formed by the gene expression of three genes (SPP1, ATXN7 and REXO1L2P), which is converted by means of a bioinformation packet into a unique score that can predict which patients will benefit from treatment with the drug, this benefit being understood as longer survival without progression and larger tumour volume reductions in response to treatment.

Potential prognostic biomarkers for CD26-targeted therapy were identified based on phase I study data of a humanized anti-CD26 monoclonal antibody YS110 against CD26-expressing tumors. Using boxplot analysis, scatter plot analysis, Pearson's product-moment correlation / Spearman's rank-difference correlation, bar graph analysis, and receiver operating characteristic (ROC), a correlation between soluble CD26 titer variation and tumor volume variation by YS110 administration, RECIST criteria evaluation, and progression-free survival (PFS) were examined. Further, mechanism of serum soluble CD26 titer variation was confirmed by in vitro experiments. As a result, serum soluble CD26 / DPP4 titer variation at an early stage of YS110 treatment was found for the first time as a predictive biomarker to evaluate a therapeutic effect.

The invention discloses a closed tumor-free drainage apparatus for abdominal tumors, which relates to the field of medical instruments, and comprises a protective sleeve, a sealing mechanism, a limiting mechanism and a sealing mechanism, the protective sleeve is used for protecting when drainage mass cyst fluid is used for reducing the volume of the tumors aiming at the huge tumors (cystic solid / cystic) of the pelvic and abdominal cavities, and the sealing mechanism is used for sealing and attaching the protective sleeve and the tumor cyst wall. The limiting device is arranged at the top of the protective sleeve and used for limiting and controlling the size of an opening in the top of the protective sleeve and sealing the whole protective sleeve after drainage operation is finished to prevent cystic fluid from flowing out to the pelvic cavity; by means of the protective sleeve, a drainage tube can penetrate through the interior of the protective sleeve to drain cyst fluid in the wrapping block in a clinical operation of excising a huge tumor of the pelvic cavity, the protective sleeve can protect drainage of the drainage tube and prevent the cyst fluid from flowing into the pelvic cavity and generating a spreading risk, and after the cyst fluid of the wrapping block is drained, the size of the wrapping block can be reduced, and the size of the wrapping block is reduced. In this way, excision operation can be conveniently conducted on the masses, and the length of an abdominal incision can be shortened during laparotomy.

The present application discloses an application of RAB32 in the preparation of products for the diagnosis, treatment and prognosis of non-small cell lung cancer. In the present application, RAB32, a member of the small GTPase RAB family, is significantly more highly expressed in non-small cell lung cancer tissues and cell lines than in adjacent cancer tissues and normal cells, and is associated with a poor prognosis. In vitro experiments show that knocking down the highly expressed RAB32 gene in tumor cells can significantly inhibit the proliferation of lung adenocarcinoma cells. In an in vivo tumor-bearing mouse model, knocking down the RAB32 gene significantly reduced the tumor volume and inhibited its growth in the knockdown group, while also inhibiting the lymph node metastasis ability of lung adenocarcinoma cells. Therefore, the RAB32 gene can be used in the preparation of products for the diagnosis, treatment and prognosis of non-small cell lung cancer.

The present invention relates to an intelligent tumor diagnosis and treatment auxiliary system and method based on a large language model, which creates a tumor computer simulation system and performs three-dimensional simulation of the tumor in the first tissue based on CT image data to obtain a first three-dimensional model, calculates its tumor volume, and selects a first treatment method when the tumor volume is greater than a preset volume threshold, otherwise the first three-dimensional model is cut in the computer simulation system and the tumor volume in each model is calculated respectively; CT image data of the tumor of the first tissue at another time point is obtained, and the tumor of the tissue is simulated in three dimensions through the computer simulation system, and the second three-dimensional model is cut after obtaining, and the tumor volume and tumor growth rate in each model after cutting are calculated respectively, and the tumor growth rate in each model is compared with the preset growth rate threshold, and the treatment method is adjusted according to the growth rate. The selection of treatment methods is assisted to improve the decision-making efficiency of treatment methods.

The invention relates to the field of tumor volume detection, and discloses a TOF technology-based tumor volume detection device for a gastrointestinal endoscope, the TOF technology-based tumor volume detection device comprises a gastrointestinal endoscope body, a detection head is mounted on one side of the gastrointestinal endoscope body, and a CCD cable, a forceps tube, an air supply tube and a water supply tube are sequentially mounted in the detection head; illumination light sources are symmetrically mounted in the middle of the detection head, a mounting block is fixedly connected to one side of the detection head, an adjusting and limiting structure is fixedly mounted on one side of the mounting block, and a scraping plate is arranged on one side of the adjusting and limiting structure. The scraping plate can be driven by the adjusting limiting structure to clean one side of the detection head, the cleaning efficiency is enhanced through the water spraying structure when the scraping plate is cleaned, the position of the TOF sensor on the mounting block can be adjusted according to requirements by utilizing the adjusting limiting structure, the size of a tumor block is measured by utilizing the TOF sensor, and the detection efficiency is improved. And real volume data of the tumor in the body is obtained.

The invention discloses a personalized preoperative risk assessment method for a spinal tumor resection operation, and the method comprises the steps: carrying out the standardization processing of features extracted from the case data of a patient and the corresponding operation plan data, and obtaining the processed features; the method comprises the following steps: preprocessing medical image data to obtain preprocessed data, performing tumor segmentation on the data through a three-dimensional attention U-Net network to obtain a tumor voxel-level probability graph, and calculating a tumor volume; obtaining the type of the tumor through the preprocessed data, the double-flow deep network and the type discrimination network; respectively carrying out standardization processing on the type, the tumor volume, the extracted wettability score and the tumor position grade to form a third feature; obtaining basic weights of the processed features and the third features from a historical database, and then dynamically adjusting the basic weights to obtain a target weight; and performing weighted summation on the target weight, the processed feature and the third feature to obtain a risk score, and matching the risk score with a preset risk score to obtain a preoperative risk assessment level.

The present invention relates to the application of stiripentol in the preparation of anti-tumor drugs, and belongs to the field of biomedical technology. The present invention has found that stiripentol used for the treatment of epilepsy can reduce the activity of tumor cells such as non-small cell lung cancer, colorectal cancer, gastric cancer, etc., reduce tumor volume, prolong the survival time of tumor mice, and has a significant anti-tumor effect; stiripentol is used in combination with chemotherapy drugs, or in combination with radiotherapy, which can significantly enhance the anti-tumor effect, and stiripentol is used in combination with chemotherapy drugs or radiotherapy. There is a synergistic effect. The present invention has discovered a new use of stiripentol and expanded the application range of stiripentol. At the same time, stiripentol has good clinical safety and no toxic side effects, providing a new choice for clinical treatment drugs for tumors.

The invention discloses a high-throughput lung cancer gene screening system and method based on CRISPR (clustered regularly interspaced short palindromic repeats), and relates to the technical field of gene screening. According to the method, full-lung three-dimensional visualization and automatic classification and identification of the lung tissue tumor can be realized without tissue slicing, and the mass center of the tumor, the structural characteristics and the interaction relationship with the host tissue are extracted in combination with a space coordinate system. On the basis, the system constructs a multi-parameter risk evaluation index system, proposes a tumor comprehensive evaluation score S based on the shortest distance d between the tumor and the lung lobe surface in combination with the tumor volume V and the ratio R of tumor cells to host cells, and introduces a dual threshold judgment mechanism to perform risk grading on different tumor types. Compared with traditional two-dimensional slice morphology or sequencing enrichment scoring, the quantitative evaluation method can accurately identify structure invasion period and in-situ stable tumors.

This invention discloses a tumor volume detection device for gastrointestinal endoscopy based on Time-of-Flight (TOF) technology, specifically in the field of tumor volume detection technology. It includes a gastrointestinal endoscope body. The front end of the endoscope body includes a CCD cable, two illumination sources, an air supply pipe, a water supply pipe, and a forceps pipe. The air supply pipe and water supply pipe are located between the two illumination sources. The CCD cable is located at the top of the forceps pipe. A mounting plate is fitted onto the outer side of the front end of the endoscope body. This invention uses an electric telescopic rod to retract a toothed plate, which, through meshing with gears, drives a drive shaft and a support plate to rotate, rotating the TOF sensor between the two illumination sources. The tumor is then irradiated by the illumination sources. During irradiation, the TOF sensor measures the size of the tumor by calculating the time difference between the time of light emission and the time of light reflection. The overall structure facilitates the measurement of tumor size.

The present application provides a prognostic marker for neoadjuvant immunotherapy and chemotherapy of lung cancer, which is the change rate of tumor volume before and after early treatment of lung cancer. In the early treatment of lung cancer, by combining the method of artificial intelligence, the volume change of tumor lesion is used as the feature of treatment effect, and it is observed from the Kaplan-Meier curve that the change amount of tumor volume has a more obvious difference between the two groups of patients.

The present invention relates to a fusion protein comprising: an interleukin-21 (IL-21) polypeptide, and an antibody or antigen binding fragment that binds at least one of CD8a, CD8aa or CD8aß having

The invention relates to the technical field of tumor treatment, and discloses a CT-guided tumor ablation dose regulation and control method and system, and the method comprises the steps: obtaining the three-dimensional contour data and gray value distribution of a tumor through CT scanning, calculating the volume and average density of the tumor, and obtaining the initial ablation dose. Initial parameters of ablation equipment are set, an ablation program is started, data are updated at specific time intervals in the ablation process, and the real-time ablation dosage is calculated. And comparing the real-time ablation dose with the initial ablation dose, and adjusting the power of ablation equipment according to a specific formula and a comparison result. The system comprises an imaging and parameter acquisition module, an initial dose calculation module, an ablation equipment control module, a real-time monitoring module, a dose comparison and regulation module and the like. The ablation dosage can be accurately regulated and controlled according to the real-time condition of a tumor, the ablation treatment effect is improved, the damage risk to normal tissue is reduced, an alarm can be given to prompt an operator when the dosage is abnormal, and the high clinical application value is achieved.

The present disclosure provides microbial consortia that are useful as therapeutics, for example, for treating cancer and / or reducing tumor volume or tumor growth in patients.

A composition of microparticles includes a non-radioactive and a radioactive isotope, and an injection vehicle, for use in the intratumoral treatment of cancer, by combined antitumoral effect of radioactivity and intratumoral microparticle deposition. The antitumoral effect provided by the cytotoxicity of radioactivity is enhanced by a modulation of the tumoral immune response induced by microparticle deposition inside the tumor, thereby decreasing the dose of radioactivity required to treat solid tumors. A method of treating solid tumors using a sub-optimal tumor-volume coverage dose of radioactivity combined with intratumoral microparticle deposition as a mean of tumor control is also disclosed.

Immunogenic compositions and systems, as well as methods for producing the immunogenic compositions, are disclosed. Also disclosed are compositions, systems, and methods of reducing cancer cell activity and treating cancer, as well as methods of reducing tumor volume and / or preventing an increase in tumor volume present in a living subject. The systems and methods involve applying an alternating electric field to cancer cells (before or after separation from a target portion of a subject), and irradiating the separated and treated cancer cells. The method may also include administering the irradiated and treated cancer cells back to the subject from which the cancer cells are separated, and / or applying an alternating electric field to the subject. The immunogenic composition includes a population of isolated and apoptotic cancer cells.

The invention provides a tumor magnetic sensitive signal extraction method and device based on an ESWAN sequence, equipment and a medium. The method comprises the following steps: acquiring a tumor phase diagram of a target part; inputting the tumor phase diagram into a preset medical image processing model, and sketching a suspected focus area in the tumor phase diagram to generate a focus sketching area; generating a three-dimensional region of interest according to the focus sketching region; based on the three-dimensional region of interest, the ratio of the magnetically sensitive signals within the volume of the tumor is obtained, and evaluation of the overall structure and heterogeneity of the tumor can be provided.

The present disclosure provides microbial consortia that are useful as therapeutics, for example, for treating cancer and / or reducing tumor volume or tumor growth in patients.

The invention relates to a predictive gene expression signature of response to antiangiogenic drugs, such as axitinib, in gastro-enteric-pancreatic and pulmonary neuroendocrine tumours. The signature is formed by the gene expression of three genes (SPP1, ATXN7 and REXO1L2P), which is converted by means of a bioinformation packet into a unique score that can predict which patients will benefit from treatment with the drug, this benefit being understood as longer survival without progression and larger tumour volume reductions in response to treatment.